This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
=== Use after MDMA === MDMA is an empathogenic-entactogenic and serotonergic psychotropic drug used primarily for recreational, though sometimes also therapeutic, purposes. Among users of MDMA, the serotonergic effects of the drug are often of particular interest and concern: After consuming MDMA, serotonin concentrations are greatly reduced in the brain. 5-HTP is necessary for serotonin production and its concentrations in the brain also decrease after taking MDMA.
Fracture mechanics was developed during World War I by English aeronautical engineer A. A. Griffith – thus the term Griffith crack – to explain the failure of brittle materials. Griffith's work was motivated by two contradictory facts:
== Diagnosis == Diagnosis of fibromyalgia is hampered by the lack of any single pathological feature, laboratory finding, or biomarker. In most cases, people with fibromyalgia symptoms may have laboratory test results that appear normal, and many of their symptoms may mimic those of other rheumatic conditions such as arthritis or osteoporosis. Specific diagnostic criteria for fibromyalgia have evolved.
=== Countercurrent exchange in sea and desert birds to conserve water === Sea and desert birds have been found to have a salt gland near the nostrils which concentrates brine, later to be "sneezed" out to the sea, in effect allowing these birds to drink seawater without the need to find freshwater resources. It also enables the seabirds to remove the excess salt entering the body when eating, swimming or diving in the sea for food. The kidney cannot remove these quantities and concentrations of salt. The salt secreting gland has been found in seabirds like pelicans, petrels, albatrosses, gulls, and terns. It has also been found in Namibian ostriches and other desert birds, where a buildup of salt concentration is due to dehydration and scarcity of drinking water. In seabirds the salt gland is above the beak, leading to a main canal above the beak, and water is blown from two small nostrils on the beak, to empty it. The salt gland has two countercurrent mechanisms working in it: a. A salt extraction system with a countercurrent multiplication mechanism, where salt is actively pumped from the blood 'venules' (small veins) into the gland tubules. Although the fluid in the tubules is with a higher concentration of salt than the blood, the flow is arranged in a countercurrent exchange, so that the blood with a high concentration of salt enters the system close to where the gland tubules exit and connect to the main canal.
Romaine (1806), speaker of the New York State Assembly Egbert Benson (1807), member of the Board of Aldermen of New York City and 4th president of the Saint Nicholas Society of the City of New York, nephew of founding father Egbert Benson Henry H. Ross (1808), U.S. congressman from New York Peter Dumont Vroom (1808), U.S. minister to Prussia and governor of New Jersey John Fine (1809), U.S. congressman from New York John Slidell (1810), Confederate minister to France and a central figure of the Trent Affair during the American Civil War; United States senator from Louisiana, brother-in-law of Admiral Matthew C. Perry Charles G. Ferris (1811), U.S. congressman from New York Van Brugh Livingston (1811), chargé d'affaires to Ecuador Nathanael G. Pendleton (1813), U.S. congressman from Ohio Samuel L. Gouverneur (1817), postmaster of New York City, private secretary, nephew, and son-in-law of President James Monroe James I. Roosevelt (1815), U.S. congressman from New York; brother of Cornelius Roosevelt William Beach Lawrence (1818), U.S. chargé d'affaires for Great Britain and acting governor of Rhode Island William F. Havemeyer (1823), three-time mayor of New York City William Duer (1824), U.S.congressman from New York John McKeon (1825): U.S. attorney, Southern District of New York; U.S. congressman from New York Hamilton Fish (1827), US secretary of state; governor of New York; United States senator from New York John Henry Hobart Haws (1827), U.S. congressman from New York John D.
Sources: en.wikipedia.org
She performed all of this contingency EVA. After 176 days, 1 hour, 18 minutes and 38 seconds in space, Caldwell Dyson landed in Kazakhstan on September 25, 2010. During this spaceflight, she completed three spacewalks, logging 22 hrs and 49 minutes of EVA work to replace a malfunctioning coolant pump.
Alistair Barkley who goes on the run with Eddie when they are framed for Alistair's murder and the destruction of his laboratory Fred Ward as FBI Agent Leon Ford, who leads the investigation to discover the cause of the destruction of the laboratory; initially focusing on Eddie and Lily, he soon suspects the involvement of government organizations Kevin Dunn as FBI Agent Doyle, Ford's assistant in the investigation who helps Ford track down Eddie, Lily, and later, C-Systems Brian Cox as Lyman Earl Collier, Chairman of C-Systems Research who is behind the conspiracy to keep the hydrogen power plant a secret Joanna Cassidy as Maggie McDermott, an old friend of Eddie's who lives in an observatory in Wisconsin, where Eddie and Lily escape to after a warrant is issued for their arrest Chelcie Ross as FBI Agent Ed Rafferty Nicholas Rudall as Dr. Alistair Barkley, head of the project to develop energy from the water who is later suffocated Tzi Ma as Lu Chen, Project Manager on the Hydrogen Project and Dr. Barkley's right-hand man; when Barkley is killed, Dr. Chen is kidnapped and forced to work at C-Systems Krzysztof Pieczyński as Lucasz Screbneski, the scientist on the original project who is secretly working for C-Systems Eddie Bo Smith Jr. and Danny Goldring as Yusef Reed and Clancy Butler, Collier's right hand men for C-Systems Margaret Travolta as Anita Fermi, Shannon's personal assistant. In addition, Michael Shannon and Neil Flynn make appearances as a van driver and a Wisconsin State Police Trooper, respectively.
== Signs and symptoms == The only sign of vitiligo is the presence of pale, patchy areas of depigmented skin, which tend to occur on the extremities. Some people may experience itching before a new patch appears. The patches are initially small, but often grow and change shape. When skin lesions occur, they are most prominent on the face, hands, and wrists. The loss of skin pigmentation is particularly noticeable around body orifices, such as the mouth, eyes, nostrils, genitalia and umbilicus. Some lesions have increased skin pigment around the edges. Additionally, the hair of affected areas can turn white or gray due to the loss of melanin. Those affected by vitiligo who are stigmatized for their condition may experience depression and similar mood disorders. Vitiligo also appears in other mammals, being conspicuous for instance on Arabian horses.
=== Discrete pathophysiology and CTS === Hereditary neuropathy with susceptibility to pressure palsies is a genetic condition that appears to increase the probability of developing CTS. Heterozygous mutations in the gene SH3TC2, associated with Charcot-Marie-Tooth, may confer susceptibility to neuropathy, including CTS. Association between common benign tumors such as lipomas, ganglion, and vascular malformation should be handled with care. Such tumors are very common and are more likely to compress the median nerve. Similarly, the association between transthyretin amyloidosis-associated polyneuropathy and carpal tunnel syndrome is under investigation. Prior carpal tunnel release is often noted in individuals who later present with transthyretin amyloid-associated cardiomyopathy. There is consideration that bilateral carpal tunnel syndrome could be a reason to consider amyloidosis, timely diagnosis of which could improve heart health. Amyloidosis is rare, even among people with carpal tunnel syndrome (0.55% incidence within 10 years of carpal tunnel release). In the absence of other factors associated with a notable probability of amyloidosis, it is not clear that biopsy at the time of carpal tunnel release has a suitable balance between potential harms and potential benefits. Other specific pathophysiologies that can cause CTS via pressure include:
The core −C(=O)−(N) of amides is called the amide group (specifically, carboxamide group). In the usual nomenclature, one adds the term "amide" to the stem of the parent acid's name. For instance, the amide derived from acetic acid is named acetamide (CH3CONH2). IUPAC recommends ethanamide, but this and related formal names are rarely encountered. When the amide is derived from a primary or secondary amine, the substituents on nitrogen are indicated first in the name. Thus, the amide formed from dimethylamine and acetic acid is N,N-dimethylacetamide (CH3CONMe2, where Me = CH3). Usually even this name is simplified to dimethylacetamide. Cyclic amides are called lactams; they are necessarily secondary or tertiary amides.
Sources: en.wikipedia.org
== Disadvantages == The Bradford assay is linear over a short range, typically from 0 μg/mL to 2000 μg/mL, often making dilutions of a sample necessary before analysis. In making these dilutions, error in one dilution is compounded in further dilutions resulting in a linear relationship that may not always be accurate. Basic conditions and detergents, such as SDS, can interfere with the dye's ability to bind to the protein through its side chains. The reagents in this method tend to stain the test tubes. Same test tubes cannot be used since the stain would affect the absorbance reading. This method is also time sensitive. When more than one solution is tested, it is important to make sure every sample is incubated for the same amount of time for accurate comparison. A limiting factor in using Coomassie-based protein determination dyes stems from the significant variation in color yield observed across different proteins This limiting factor is notably evident in collagen-rich protein samples, like pancreatic extracts, where both the Lowry and Bradford methods tend to underestimate protein content. It is also inhibited by the presence of detergents, although this problem can be alleviated by the addition of cyclodextrins to the assay mixture. Much of the non-linearity stems from the equilibrium between two different forms of the dye which is perturbed by adding the protein. The Bradford assay linearizes by measuring the ratio of the absorbances, 595 over 450 nm. This modified Bradford assay is approximately 10 times more sensitive than the conventional one.
Propranolol is a medication of the beta blocker class. It is used to treat high blood pressure, some types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, akathisia, performance anxiety, and essential tremors, as well as to prevent migraine headaches, and to prevent further heart problems in those with angina or previous heart attacks. It can be taken orally, rectally, or by intravenous injection. The formulation that is taken orally comes in short-acting and long-acting versions. Propranolol appears in the blood after 30 minutes and has a maximum effect between 60 and 90 minutes when taken orally. Common side effects include nausea, abdominal pain, and constipation. It may worsen the symptoms of asthma. Propranolol may cause harmful effects for the fetus if taken during pregnancy; however, its use during breastfeeding is generally considered to be safe. It is a non-selective beta blocker which works by blocking β-adrenergic receptors. Propranolol was patented in 1962 and approved for medical use in 1964. It is on the World Health Organization's List of Essential Medicines. Propranolol is available as a generic medication. In 2023, it was the 69th most commonly prescribed medication in the United States, with more than 9 million prescriptions.
== Further reading == Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. doi:10.1097/PRS.0000000000006327. PMC 6940025. PMID 31609882. Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. doi:10.1007/s40265-021-01631-w. PMC 8648634. PMID 34787840.
== Reactions == Hippuric acid is readily hydrolysed by hot caustic alkalis to benzoic acid and glycine. Nitrous acid converts it into benzoyl glycolic acid, C6H5C(=O)OCH2CO2H. Its ethyl ester reacts with hydrazine to form hippuryl hydrazine, C6H5CONHCH2CONHNH2, which was used by Theodor Curtius for the preparation of hydrazoic acid. Hippuric acid has also been used in Erlenmeyer–Plöchl synthesis of phenylalanine and other amino acids, the reaction proceeding via an oxazolone or "azlactone" intermediate.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.